AKEBIA THERAPEUTICS INC (AKBA:NASDAQ)
$0.9398 0.0333 (3.6735%)
Analysed AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) News Sources
Akebia (AKBA) Q1 2026 Earnings Transcript
08-05-2026
fool.com
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
28-05-2026
yahoo.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01-06-2026
yahoo.com
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
05-06-2026
marketbeat.com
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
10-06-2026
yahoo.com
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
30-06-2026
yahoo.com
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
29-07-2026
yahoo.com
Akebia Therapeutics Q2 Earnings Call Highlights
05-08-2026
marketbeat.com
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
05-08-2026
yahoo.com
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
06-08-2026
yahoo.com
What is the current price of AKEBIA THERAPEUTICS INC (AKBA:NASDAQ)?
The current price of AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) is $0.9398.
AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) absolute price change since previous trading day?
The absolute price change of AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) since the previous trading day is $0.0333.
AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) percentage price change since previous trading day?
The percentage price change of AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) since the previous trading day is 3.6735%.
What is the most recent average sentiment score for AKEBIA THERAPEUTICS INC (AKBA:NASDAQ)?
The most recent average sentiment score for AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for AKEBIA THERAPEUTICS INC (AKBA:NASDAQ)?
The most recent sentiment for AKEBIA THERAPEUTICS INC (AKBA:NASDAQ) is .
SEC-8K** Filing Available For AKEBIA THERAPEUTICS INC (AKBA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.